Media headlines about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive on Thursday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 48.0675558991603 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Infinity Pharmaceuticals (INFI) opened at $2.06 on Thursday. Infinity Pharmaceuticals has a 12-month low of $0.93 and a 12-month high of $3.84.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $14.70 million. During the same period last year, the business earned ($0.39) earnings per share. research analysts anticipate that Infinity Pharmaceuticals will post -0.93 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Wells Fargo & Company raised Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th. Finally, ValuEngine cut Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/11/23/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-infinity-pharmaceuticals-infi-share-price.html.
In other news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The stock was purchased at an average cost of $1.26 per share, with a total value of $2,016,057.96. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.81% of the stock is owned by company insiders.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.